{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:28:26Z","timestamp":1793640506176,"version":"4.5.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.clml.2017.09.003","type":"journal-article","created":{"date-parts":[[2017,12,9]],"date-time":"2017-12-09T18:09:33Z","timestamp":1512842973000},"page":"e51-e60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-5883","authenticated-orcid":false,"given":"Pallawi","family":"Torka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyank","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema A.","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron S.","family":"Czuczman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin P.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Deeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishala","family":"Neppalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Mavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.09.003_bib1","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.4049\/jimmunol.151.9.4494","article-title":"Association of tyrosine and serine kinases with the B cell surface antigen CD20: induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2","volume":"151","author":"Deans","year":"1993","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2017.09.003_bib2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0952-7915(99)00010-2","article-title":"Signaling antibodies in cancer therapy","volume":"11","author":"Cragg","year":"1999","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.clml.2017.09.003_bib3","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","article-title":"Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms","volume":"51","author":"Harjunpaa","year":"2000","journal-title":"Scand J Immunol"},{"issue":"16 Pt 1","key":"10.1016\/j.clml.2017.09.003_bib4","first-page":"5866","article-title":"Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model","volume":"9","author":"Hernandez-Ilizaliturri","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.09.003_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/bcmd.2000.0287","article-title":"Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis","volume":"26","author":"Hofmeister","year":"2000","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.clml.2017.09.003_bib6","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/eji.1830251126","article-title":"Engagement of CD20 suppresses apoptosis in germinal center B cells","volume":"25","author":"Holder","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.clml.2017.09.003_bib7","first-page":"7170","article-title":"Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways","volume":"60","author":"Mathas","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2017.09.003_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0161-5890(98)00042-X","article-title":"The association between CD20 and Src-family tyrosine kinases requires an additional factor","volume":"35","author":"Popoff","year":"1998","journal-title":"Mol Immunol"},{"key":"10.1016\/j.clml.2017.09.003_bib9","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.003_bib10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s002620050016","article-title":"Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells","volume":"48","author":"Shan","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clml.2017.09.003_bib11","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1349-7006.1998.tb03280.x","article-title":"Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody","volume":"89","author":"Taji","year":"1998","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.clml.2017.09.003_bib12","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1080\/17402520500182329","article-title":"Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model","volume":"46","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.09.003_bib13","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1200\/JCO.2007.13.7729","article-title":"Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study","volume":"26","author":"Cartron","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.003_bib14","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3109\/10428194.2014.974049","article-title":"A\u00a0phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia","volume":"56","author":"Strati","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.09.003_bib15","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.leu.2402995","article-title":"Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy","volume":"17","author":"van der Kolk","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.09.003_bib16","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly\u00a0\u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.003_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-1759(98)00136-7","article-title":"A\u00a0simple flow cytometry assay using dihydrorhodamine for the measurement of the neutrophil respiratory burst in whole blood: comparison with the quantitative nitrobluetetrazolium test","volume":"219","author":"Richardson","year":"1998","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.clml.2017.09.003_bib18","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2141.2011.08669.x","article-title":"Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas","volume":"153","author":"Brem","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.09.003_bib19","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","article-title":"Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels","volume":"14","author":"Czuczman","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.09.003_bib20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.09.003_bib21","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.6004\/jnccn.2014.0125","article-title":"Non-Hodgkin's lymphomas, version 4.2014","volume":"12","author":"Zelenetz","year":"2014","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.clml.2017.09.003_bib22","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.003_bib23","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.003_bib24","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.003_bib25","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.003_bib26","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study","volume":"27","author":"Hochster","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.003_bib27","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.003_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2017.09.003_bib29","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.003_bib30","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.003_bib31","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood.V124.21.800.800","article-title":"Ibrutinib monotherapy in relapsed\/refractory follicular lymphoma (FL): preliminary results of a phase 2 consortium (P2C) trial","volume":"124","author":"Bartlett","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.003_bib32","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in\u00a0patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.09.003_bib33","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.003_bib34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.12755","article-title":"Lenalidomide plus rituximab can\u00a0produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma","volume":"165","author":"Tuscano","year":"2014","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017309692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017309692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:56:52Z","timestamp":1793638612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017309692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S2152265017309692"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.09.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}